Cristofanilli, et al.. Predictors of Prolonged Benefit from Palbociclib Plus Fulvestrant in Women with Endocrine-resistant Hormone Receptor–positive/human Epidermal Growth Factor Receptor 2–negative Metastatic Breast Cancer in PALOMA-3. Elsevier BV, 2018, doi:10.1016/j.ejca.2018.08.011.